Business
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previ
About this update from Herantis Pharma Plc
[{"type":"image","alt":"Herantis Pharma plc","displaySize":"","headline":null,"caption":"Herantis Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TztkX3djp9fmQ02UkZu7vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646","width":300,"height":51}},"lazy":false},{"type":"text","content":"Key step achieved in advancing HER-096 towards Phase 2 efficacy trial ","length":69,"tagName":"p"},{"type":"text","content":"Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previous pre-clinical and clinical data. These results provide further confidence in the compound’s suitability for long-term administration and represent another important milestone on the path towards a Phase 2 clinical efficacy trial.","length":662,"tagName":"p"},{"type":"text","content":"“The successful completion of this long-term toxicology study marks another important step forward for our HER-096 program”, said Henri Huttunen, CSO of Herantis Pharma. “Together with the positive results from our Phase 1b trial, we now have a comprehensive safety and pharmacokinetic dataset that provides a strong foundation for advancing HER-096 into Phase 2 clinical development. We are excited by the growing body of evidence for HER-096 as a potentially game-changing therapy that could become the first disease-modifying and neurorestorative treatment for Parkinson’s disease.”","length":585,"tagName":"p"},{"type":"text","content":"The completion of the preclinical toxicology program also marks the final milestone of the EIC Accelerator Grant project, which began in 2023. The grant of EUR 2.5 million also enabled Herantis to advance its biomarker development program, the results of which have already been applied in exploratory biomarker analyses within the Phase 1b clinica...